The effects of cannabinoids on the brain
by
Ameri A
Department of Pharmacy and
Pharmacology of Natural Compounds,
University of
Ulm, Germany.
Prog Neurobiol 1999 Jul; 58(4):315-48
ABSTRACT
Cannabinoids have a long history of consumption for recreational and medical
reasons. The primary active constituent of the hemp plant Cannabis sativa is
delta9-tetrahydrocannabinol (delta9-THC). In humans, psychoactive cannabinoids
produce euphoria, enhancement of sensory perception, tachycardia,
antinociception, difficulties in concentration and impairment of memory. The
cognitive deficiencies seem to persist after withdrawal. The toxicity of
marijuana has been underestimated for a long time, since recent findings
revealed delta9-THC-induced cell death with shrinkage of neurons and DNA
fragmentation in the hippocampus. The acute effects of cannabinoids as well as
the development of tolerance are mediated by G protein-coupled cannabinoid
receptors. The CB1 receptor and its splice variant CB1A, are found predominantly
in the brain with highest densities in the hippocampus, cerebellum and striatum.
The CB2 receptor is found predominantly in the spleen and in haemopoietic cells
and has only 44% overall nucleotide sequence identity with the CB1 receptor. The
existence of this receptor provided the molecular basis for the
immunosuppressive actions of marijuana. The CB1 receptor mediates inhibition of
adenylate cyclase, inhibition of N- and P/Q-type calcium channels, stimulation
of potassium channels, and activation of mitogen-activated protein kinase. The
CB2 receptor mediates inhibition of adenylate cyclase and activation of
mitogen-activated protein kinase. The discovery of endogenous cannabinoid
receptor ligands, anandamide (N-arachidonylethanolamine) and
2-arachidonylglycerol made the notion of a central cannabinoid neuromodulatory
system plausible. Anandamide is released from neurons upon depolarization
through a mechanism that requires calcium-dependent cleavage from a phospholipid
precursor in neuronal membranes. The release of anandamide is followed by rapid
uptake into the plasma and hydrolysis by fatty-acid amidohydrolase. The
psychoactive cannabinoids increase the activity of dopaminergic neurons in the
ventral tegmental area-mesolimbic pathway. Since these dopaminergic circuits are
known to play a pivotal role in mediating the reinforcing (rewarding) effects of
the most drugs of abuse, the enhanced dopaminergic drive elicited by the
cannabinoids is thought to underlie the reinforcing and abuse properties of
marijuana. Thus, cannabinoids share a final common neuronal action with other
major drugs of abuse such as morphine, ethanol and nicotine in producing
facilitation of the mesolimbic dopamine system.
Reward
Cannabis
Dopamine
Cannabinoids
Drug screening
The hungry hydra
The nectar of delight
The pregnant smoker
Why is cannabis fun?
Abstinence syndrome
Cannabinoid antagonists
Cannabis and cannabinoids
Cannabinoids/neurogenesis
Cannabinoids, opioids and pain
Cannabis seeds and stoned mice
Cannabinoids in vitro and in vivo
Refs
HOME
HedWeb
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family